Treace to Report Third Quarter 2024 Financial Results on November 5, 2024
Treace Medical Concepts, Inc. (NasdaqGS: TMCI), a medical technology company specializing in surgical treatments for bunions and midfoot deformities, has announced it will release its third quarter 2024 financial results after market close on Tuesday, November 5, 2024. The company will host a conference call at 4:30 pm ET to discuss the results.
Investors can participate in the call by registering to receive dial-in numbers and a unique pin. Additionally, a live and archived webcast of the event will be available on the company's investor relations website at https://investors.treace.com/.
Treace Medical Concepts, Inc. (NasdaqGS: TMCI), una società di tecnologia medica specializzata in trattamenti chirurgici per ipercheratosi e deformità del mesopiede, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 dopo la chiusura del mercato il martedì 5 novembre 2024. L'azienda ospiterà una chiamata di conferenza alle 4:30 pm ET per discutere i risultati.
Gli investitori possono partecipare alla chiamata registrandosi per ricevere i numeri per la connessione e un pin unico. Inoltre, un webcast dal vivo e registrato dell'evento sarà disponibile sul sito web delle relazioni con gli investitori della società all'indirizzo https://investors.treace.com/.
Treace Medical Concepts, Inc. (NasdaqGS: TMCI), una empresa de tecnología médica especializada en tratamientos quirúrgicos para juanetes y deformidades del mediopié, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 después del cierre del mercado el martes 5 de noviembre de 2024. La empresa realizará una llamada de conferencia a las 4:30 pm ET para discutir los resultados.
Los inversores pueden participar en la llamada registrándose para recibir los números de acceso y un pin único. Además, un webcast en vivo y grabado del evento estará disponible en el sitio web de relaciones con inversores de la empresa en https://investors.treace.com/.
Treace Medical Concepts, Inc. (NasdaqGS: TMCI), 수술적 치료를 전문으로 하는 의료 기술 회사로서 건막류와 중족골 변형에 대해 발표했습니다. 이 회사는 2024년 3분기 재무 결과를 2024년 11월 5일 화요일 시장 마감 후 발표할 것이라고 발표했습니다. 회사는 오후 4:30 ET에 결과를 논의하기 위해 컨퍼런스 콜을 개최합니다.
투자자는 다이얼 인 번호와 고유 PIN을 수신하기 위해 등록하여 전화 회의에 참여할 수 있습니다. 또한, 실시간 및 아카이브 웹캐스트가 회사의 투자자 관계 웹사이트 https://investors.treace.com/에서 제공될 것입니다.
Treace Medical Concepts, Inc. (NasdaqGS: TMCI), une entreprise de technologie médicale spécialisée dans les traitements chirurgicaux pour hallux valgus et déformations du médio-pied, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 après la clôture du marché le Mardi 5 novembre 2024. La société organisera une conférence téléphonique à 16h30 ET pour discuter des résultats.
Les investisseurs peuvent participer à l'appel en s'inscrivant pour recevoir les numéros d'accès et un code PIN unique. De plus, un webinaire en direct et archivés de l'événement sera disponible sur le site Web des relations avec les investisseurs de l'entreprise à l'adresse https://investors.treace.com/.
Treace Medical Concepts, Inc. (NasdaqGS: TMCI), ein Medizintechnikunternehmen, das auf chirurgische Behandlungen für Hallux valgus und Mittelfußdeformitäten spezialisiert ist, hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 nach Handelsende am Dienstag, den 5. November 2024 veröffentlichen wird. Das Unternehmen wird um 16:30 Uhr ET eine Konferenzschaltung abhalten, um die Ergebnisse zu besprechen.
Anleger können an dem Anruf teilnehmen, indem sie sich registrieren, um die Durchwahl-Nummern und eine einmalige PIN zu erhalten. Darüber hinaus wird ein Live- und Archiv-Webcast der Veranstaltung auf der Investor-Relations-Website des Unternehmens unter https://investors.treace.com/ verfügbar sein.
- None.
- None.
PONTE VEDRA, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Tuesday, November 5, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.
Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net
FAQ
When will Treace Medical Concepts (TMCI) release its Q3 2024 financial results?
How can investors participate in Treace Medical Concepts' (TMCI) Q3 2024 earnings call?
Where can I find the webcast of Treace Medical Concepts' (TMCI) Q3 2024 earnings call?
What are the main products of Treace Medical Concepts (TMCI)?
